RecruitingPhase 1NCT05591027

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Oregon Health and Science University
Principal Investigator
Amala Soumyanath, Ph.D
Oregon Health and Science University
Intervention
Centella asiatica product(drug)
Enrollment
48 target
Eligibility
60-85 years · All sexes
Timeline
20222026

Study locations (1)

Collaborators

Alzheimer's Association

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05591027 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease

← Back to all trials